Diagnosing and Treating Lyme disease: The First Sign is not always a rash

By Margaret Dayhoff-Brannigan, PhD November 2014 Lyme disease infects approximately 300,000 people each year. Unfortunately, less than 50% of these people will develop the bull’s-eye rash that is the well-known early sign of the disease. Lyme disease is commonly misdiagnosed … Continue reading

Comments on Intent to Exempt Certain Medical Devices from Premarket Notification Requirements

We strongly urge the FDA to reassess the Submission Type for certain medical devices and continue to require 510(K) clearance due to the high number of MAUDE reports, including numerous deaths from these devices. Devices that can cause fatal adverse events should not be exempt from FDA regulation. Continue reading

Comments on Distributing Risk Information for Approved Prescription Drugs and Biological Products

August 25, 2014. As members of the Patient, Consumer and Public Health Coalition, we strongly urge the Food and Drug Administration (FDA) to withdraw its draft guidance proposing to allow pharmaceutical firms to distribute to health care providers and facilities scientific medical literature suggesting that the risk information for prescription drugs and biological products are less than what is stated in the FDA-approved product labeling. Continue reading

You’re Invited to a Conference: How Can Healthcare be Improved with Comparative Effectiveness Research?

Register Now for our March 18th Conference in Washington, D.C. on “How Can Healthcare be Improved with Comparative Effectiveness Research,” co-sponsored by Consumer Reports. If you’re a leader in public health or health policy, or you represent consumers, patients or health professionals, you won’t want to miss this! Continue reading